The Cerebellum

, Volume 14, Issue 2, pp 128–132 | Cite as

Spinal Cord Damage in Machado-Joseph Disease

  • Camila N. Fahl
  • Lucas Melo T. Branco
  • Felipe P. G. Bergo
  • Anelyssa D’Abreu
  • Iscia Lopes-Cendes
  • Marcondes C. FrançaJr
Original Paper


Machado-Joseph disease (SCA3) is the most frequent spinocerebellar ataxia worldwide and characterized by remarkable phenotypic heterogeneity. MRI-based studies in SCA3 focused in the cerebellum and connections, but little is known about cord damage in the disease and its clinical relevance. To evaluate the spinal cord damage in SCA3 through quantitative analysis of MRI scans. A group of 48 patients with SCA3 and 48 age and gender-matched healthy controls underwent MRI on a 3T scanner. We used T1-weighted 3D images to estimate the cervical spinal cord area (CA) and eccentricity (CE) at three C2/C3 levels based on a semi-automatic image segmentation protocol. The scale for assessment and rating of ataxia (SARA) was employed to quantify disease severity. The two groups—SCA3 and controls—were significantly different regarding CA (49.5 ± 7.3 vs 67.2 ± 6.3 mm2, p < 0.001) and CE values (0.79 ± 0.06 vs 0.75 ± 0.05, p = 0.005). In addition, CA presented a significant correlation with SARA scores in the patient group (p = 0.010). CE was not associated with SARA scores (p = 0.857). In the multiple variable regression, we found that disease duration was the only variable associated with CA (coefficient = −0.629, p = 0.025). SCA3 is characterized by cervical cord atrophy and antero-posterior flattening. In addition, the spinal cord areas did correlate with disease severity. This suggests that quantitative analyses of the spinal cord MRI might be a useful biomarker in SCA3.


Spinal cord MRI Ataxia Machado-Joseph disease SCA3 


  1. 1.
    D’Abreu A, França Jr MC, Paulson HL, Lopes-Cendes I. Caring for Machado-Joseph disease: current understanding and how to help patients. Parkinsonism Relat Disord. 2010;16:2–7.CrossRefPubMedCentralPubMedGoogle Scholar
  2. 2.
    Maruyama H, Nakamura S, Matsuyama Z, Sakai T, Doyu M, Sobue G, et al. Molecular features of the CAG repeats and clinical manifestation of Machado–Joseph disease. Hum Mol Genet. 1995;4:807–12.CrossRefPubMedGoogle Scholar
  3. 3.
    Kawaguchi Y, Okamoto T, Taniwaki M, Aizawa M, Inoue M, Katayama S, et al. CAG expansions in a novel gene for Machado–Joseph disease at chromosome 14q32.1. Nat Genet. 1994;8:221–8.CrossRefPubMedGoogle Scholar
  4. 4.
    Williams AJ, Paulson HL. Polyglutamine neurodegeneration: protein misfolding revisited. Trends Neurosci. 2008;31:521–8.CrossRefPubMedCentralPubMedGoogle Scholar
  5. 5.
    Rub U, Brunt ER, Deller T. New insights into the pathoanatomy of spinocerebellar ataxia type 3 (Machado–Joseph disease). Curr Opin Neurol. 2008;21:111–6.CrossRefPubMedGoogle Scholar
  6. 6.
    Lopes TM, D’Abreu A, França Jr MC, Yasuda CL, Betting LE, Samara AB, et al. Widespread neuronal damage and cognitive dysfunction in spinocerebellar ataxia type 3. J Neurol. 2013;260:2370–9.CrossRefPubMedGoogle Scholar
  7. 7.
    Guimarães RP, D’Abreu A, Yasuda CL, França Jr MC, Silva BH, Cappabianco FA, et al. A multimodal evaluation of microstructural white matter damage in spinocerebellar ataxia type 3. Mov Disord. 2013;28:1125–32.CrossRefPubMedGoogle Scholar
  8. 8.
    D’Abreu A, Franca Jr MC, Yasuda CL, Campos BA, Lopes-Cendes I, Cendes F. Neocortical atrophy in Machado–Joseph disease: a longitudinal neuroimaging study. J Neuroimaging. 2012;22:285–91.CrossRefPubMedGoogle Scholar
  9. 9.
    Klockgether T, Skalej M, Wedekind D, Luft AR, Welte D, Schulz JB, et al. Autosomal dominant cerebellar ataxia type I. MRI-based volumetry of posterior fossa structures and basal ganglia in spinocerebellar ataxia types 1, 2 and 3. Brain. 1998;121:1687–93.CrossRefPubMedGoogle Scholar
  10. 10.
    Rüb U, Seidel K, Ozerden I, et al. Consistent affection of the central somatosensory system in spinocerebellar ataxia type 2 and type 3 and its significance for clinical symptoms and rehabilitative therapy. Brain Res Rev. 2007;53:235–49.CrossRefPubMedGoogle Scholar
  11. 11.
    Riess O, Rüb U, Pastore A, Bauer P, Schöls L. SCA3: neurological features, pathogenesis and animal models. Cerebellum. 2008;7:125–37.CrossRefPubMedGoogle Scholar
  12. 12.
    Shimizu H, Yamada M, Toyoshima Y, et al. Involvement of Onuf’s nucleus in Machado-Joseph disease: a morphometric and immunohistochemical study. Acta Neuropathol. 2010;120:439–48.CrossRefPubMedGoogle Scholar
  13. 13.
    Agosta F, Rocca MA, Valsasina P, et al. A longitudinal diffusion tension MRI study of the cervical cord and brain in amyotrophic lateral sclerosis patients. J Neurol Neurosurg Psychiatry. 2009;80:53–5.CrossRefPubMedGoogle Scholar
  14. 14.
    Chevis CF, da Silva CB, D’Abreu A, Lopes-Cendes I, Cendes F, França Jr MC, et al. Spinal cord atrophy correlates with disability in Friedreich’s ataxia. Cerebellum. 2013;12:43–7.CrossRefPubMedGoogle Scholar
  15. 15.
    Branco LM, De Albuquerque M, De Andrade HM, Bergo FP, Nucci A, França Jr MC. Spinal cord atrophy correlates with disease duration and severity in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15:93–7.CrossRefPubMedGoogle Scholar
  16. 16.
    Lukas C, Hahn HK, Bellenberg B, Hellwig K, Globas C, Schimrigk SK, et al. Spinal cord atrophy in spinocerebellar ataxia type 3 and 6: impact on clinical disability. J Neurol. 2008;255:1244–9.CrossRefPubMedGoogle Scholar
  17. 17.
    Braga-Neto P, Godeiro-Junior C, Dutra LA, Pedroso JL, Barsottini OG. Translation and validation into Brazilian version of the Scale of the Assessment and Rating of Ataxia (SARA). Arq Neuropsiquiatr. 2010;68:228–30.CrossRefPubMedGoogle Scholar
  18. 18.
    Bergo FPG, França MC Jr., Chevis CF, Cendes F. SpineSeg: A 2012 Segmentation and Measurement Tool for Evaluation of Spinal Cord Atrophy. In: CISTI’2012 (7ª Conferencia Ibérica de Sistemas y Tecnologia de Información);; Madrid, Spain. IEEE; 2012. p. 400–403Google Scholar
  19. 19.
    Fischl B, Salat DH, Busa E, Albert M, Dieterich M, Haselgrove C, et al. Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain. Neuron. 2002;33:341–55.CrossRefPubMedGoogle Scholar
  20. 20.
    França Jr MC, D’Abreu A¸ Nucci A, Cendes F, Lopes-Cendes I. Prospective study of peripheral neuropathy in Machado-Joseph disease. Muscle Nerve. 2009;40:1012–8.CrossRefGoogle Scholar
  21. 21.
    Escorcio Bezerra ML, Pedroso JL, Pinheiro DS, Braga-Neto P, Povoas Barsottini OG, et al. Pattern of peripheral nerve involvement in Machado-Joseph disease: neuronopathy or distal axonopathy? A clinical and neurophysiological evaluation. Eur Neurol. 2013;69:129–33.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  • Camila N. Fahl
    • 1
  • Lucas Melo T. Branco
    • 1
  • Felipe P. G. Bergo
    • 1
  • Anelyssa D’Abreu
    • 1
  • Iscia Lopes-Cendes
    • 2
  • Marcondes C. FrançaJr
    • 1
    • 3
  1. 1.Department of Neurology and Neuroimaging LaboratoryUniversity of Campinas (UNICAMP)CampinasBrazil
  2. 2.Department of Medical GeneticsUniversity of Campinas (UNICAMP)CampinasBrazil
  3. 3.Department of NeurologyUniversity of Campinas – UNICAMPCampinasBrazil

Personalised recommendations